These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29317342)

  • 1. Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model.
    Long Q; Lin TY; Huang Y; Li X; Ma AH; Zhang H; Carney R; Airhart S; Lam KS; deVere White RW; Pan CX; Li Y
    Nanomedicine; 2018 Apr; 14(3):789-799. PubMed ID: 29317342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer.
    Lin TY; Li Y; Liu Q; Chen JL; Zhang H; Lac D; Zhang H; Ferrara KW; Wachsmann-Hogiu S; Li T; Airhart S; deVere White R; Lam KS; Pan CX
    Biomaterials; 2016 Oct; 104():339-51. PubMed ID: 27479049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy.
    Lin TY; Guo W; Long Q; Ma A; Liu Q; Zhang H; Huang Y; Chandrasekaran S; Pan C; Lam KS; Li Y
    Theranostics; 2016; 6(9):1324-35. PubMed ID: 27375782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
    Nam S; Kim H; Hong D; Park JB; Kim SJ
    Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
    Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
    Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Tumor Microenvironment-Responsive Biodegradable Mesoporous Nanosystem for Anti-Inflammation and Cancer Theranostics.
    Wu J; Niu S; Bremner DH; Nie W; Fu Z; Li D; Zhu LM
    Adv Healthc Mater; 2020 Jan; 9(2):e1901307. PubMed ID: 31814332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
    Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
    Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
    J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.
    Xu Y; Zhu Q; Chen D; Shen Z; Wang W; Ning G; Zhu Y
    Tumour Biol; 2015 Jul; 36(7):5103-8. PubMed ID: 25682284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer.
    Ma L; Sato F; Sato R; Matsubara T; Hirai K; Yamasaki M; Shin T; Shimada T; Nomura T; Mori K; Sumino Y; Mimata H
    Oncol Rep; 2014 Jun; 31(6):2482-92. PubMed ID: 24718854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of a porous coordination network and black phosphorus nanosheets for improved photodynamic therapy of tumor.
    Liu MD; Yu Y; Guo DK; Wang SB; Li CX; Gao F; Zhang C; Xie BR; Zhong Z; Zhang XZ
    Nanoscale; 2020 Apr; 12(16):8890-8897. PubMed ID: 32266902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer.
    Ghalhar MG; Akbarzadeh A; Rahmati M; Mellatyar H; Dariushnejad H; Zarghami N; Barkhordari A
    Asian Pac J Cancer Prev; 2014; 15(17):7113-8. PubMed ID: 25227799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.
    Karkoulis PK; Stravopodis DJ; Voutsinas GE
    Tumour Biol; 2016 May; 37(5):6861-73. PubMed ID: 26662567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of Folic Acid-Targeted Temperature-Sensitive Magnetoliposomes and their Antitumor Effects In Vitro and In Vivo.
    Wang X; Yang R; Yuan C; An Y; Tang Q; Chen D
    Target Oncol; 2018 Aug; 13(4):481-494. PubMed ID: 29992403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.
    O'Malley KJ; Langmann G; Ai J; Ramos-Garcia R; Vessella RL; Wang Z
    Prostate; 2012 Jul; 72(10):1117-23. PubMed ID: 22161776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
    Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
    Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-delivery of paclitaxel and tanespimycin in lipid nanoparticles enhanced anti-gastric-tumor effect in vitro and in vivo.
    Ma L; Yang D; Li Z; Zhang X; Pu L
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):904-911. PubMed ID: 29757014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.